title: HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment.
abstract: The aim of this study was to evaluate residual viral replication by assessing the HIV load of circulating infected cells in patients given an effective antiprotease-containing treatment for 1 year. PBMC HIV RNA and HIV DNA was quantified by techniques standardized and evaluated by interlaboratory quality control testing. Viral markers identified in a multicenter study were validated in a cross-sectional study of 121 patients beginning treatment. A longitudinal study of 3 viral markers was carried out in 18 patients, each of whom had fewer than 200 copies of HIV RNA per milliliter of plasma after 12 months of treatment. The cross-sectional study showed that viral replication in PBMCs was correlated with the number of circulating infected cells (Spearman rank correlation; p = 0.0001, r = 0.35) and the concentration of virus particles in the plasma (Spearman; p = 0.0001, r = 0.54). The longitudinal study showed that the decrease in HIV RNA levels was smaller in PBMCs than in the plasma. The largest decrease in HIV DNA levels after 12 months of treatment was recorded in patients with low levels of intracellular replication (Spearman; p = 0.005, r = 0.69). PBMC HIV RNA and HIV DNA levels were very informative markers, complementary to plasma HIV RNA levels. They should be used in future trials evaluating the long-term efficacy of new associations of highly active antiretroviral treatments.
authors.affiliation: Laboratoire de Virologie, CHU Necker-Enfants Malades, 75015 Paris, France. marianne.burgard@nck.ap-hop-paris.fr
authors.forename: M
authors.initials: M
authors.lastname: Burgard
authors.forename: J
authors.initials: J
authors.lastname: Izopet
authors.forename: B
authors.initials: B
authors.lastname: Dumon
authors.forename: C
authors.initials: C
authors.lastname: Tamalet
authors.forename: D
authors.initials: D
authors.lastname: Descamps
authors.forename: A
authors.initials: A
authors.lastname: Ruffault
authors.forename: A
authors.initials: A
authors.lastname: Vabret
authors.forename: G
authors.initials: G
authors.lastname: Bargues
authors.forename: M
authors.initials: M
authors.lastname: Mouroux
authors.forename: I
authors.initials: I
authors.lastname: Pellegrin
authors.forename: S
authors.initials: S
authors.lastname: Ivanoff
authors.forename: O
authors.initials: O
authors.lastname: Guisthau
authors.forename: V
authors.initials: V
authors.lastname: Calvez
authors.forename: J M
authors.initials: JM
authors.lastname: Seigneurin
authors.forename: C
authors.initials: C
authors.lastname: Rouzioux
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D003430:Cross-Sectional Studies; D004279:DNA, Viral / Q000097:blood*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology*; D008137:Longitudinal Studies; D012367:RNA, Viral / Q000097:blood*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D004279:DNA, Viral; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors